Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...